QV Bioelectronics, based in Cheshire, is a seed-stage start-up company developing an implantable medical device for the treatment of brain tumours utilising electrical field therapy (EFT). EFT is an emerging treatment modality that has demonstrated transformative clinical outcomes and has received FDA approval for Glioblastoma, the most common and most aggressive brain tumour in adults. However, the efficacy of the existing solution is limited by dosing compliance and leads to poor patent quality of life. QV Bioelectronics’ innovative implant, GRACE, overcomes these issues and as a result, is expected to deliver a 10X increase in the 5-year survival of GBM patients compared to the current standard of care. They are currently in pre-clinical development and are expecting to be able to commence a first in a human clinical trial in 2024.
They are now seeking a Non-Executive Chair of the board of directors to help lead the direction of the company over the next few years.
The role demands an expert in MedTech, with experience as a Chair and in fundraising for early-stage companies (ideally well networked with investors in the sector) Experience with Class III medical devices, ideally taking them through the development stages to clinical launch would be highly advantageous as would experience in setting up clinical trials (development of partnerships with hospital systems & development of trial design).
The role requires a commitment of between 0.5 and 1 day a month, which will be reimbursed through a mixture of cash and equity.
For more information or to make an application please email Chris Bullock, CEO & Co-Founder at firstname.lastname@example.org